A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids. Among a cohort of patients with severe asthma using the biologic ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- ...

For patients with severe eosinophilic asthma controlled on bevacizumab, tapering of inhaled corticosteroids (ICS) is feasible and is not associated with worse asthma control, according to a study ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...

Most patients with severe asthma who were treated with the biologic therapy benralizumab were able to reduce their dose of inhaled corticosteroid (ICS), and more than half could stop steroid use ...

Phase 2b study to evaluate novel inhaled therapeutic in patients with inadequately controlled asthma despite medium-to-high dose ICS/LABA therapy BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a ...